source
- Teva reports positive mid-stage results for celiac disease antibody, BioMarin settles patent fight with AscendisTeva said its experimental antibody TEV-408 showed statistically significant and clinically meaningful reduction in gluten-induced intestinal damage in a mid-stage trial for celiac disease. The tr…
- UniQure submits experimental Huntington's gene therapy to FDA for accelerated reviewUniQure announced that it has filed its experimental gene therapy for Huntington's disease with the U.S. Food and Drug Administration, seeking accelerated approval. The submission follows earlier…